ClinicalTrials.gg
CompletedNCT06195787Updated May 15, 2025

Improving Emergency Department Testing for Deep Vein Thrombosis

An observational study in Deep Vein Thrombosis (DVT), sponsored by Dr. Kerstin de Wit. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by Dr. Kerstin de Wit · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
458
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Venous Thrombosis with a site in Canada — 5 open to participants now, 8 under way, 3 of them phase 3. Venous Thrombosis · Canada.

Enrollment
13th of 27
458 · median 366
Started
2024
with 1 other
Observational
27 of 106
none open now
Registered
101st of 106
by date

Among the 106 studies in Venous Thrombosis with a site in Canada, this one is the 13th largest by enrollment of the 27 observational ones that give a count, is one of 2 that started in 2024, is one of 27 observational ones, and was the 101st registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

5 of the 106 studies in Venous Thrombosis with a site in Canada are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Venous Thrombosis with a site in Canada, or all of them as a file.
02

Study summary

This observational study will use a new way to test for deep vein thrombosis (DVT) of the leg. A DVT is a blood clot in the leg and is a medical problem that can cause swelling, pain, and redness. If the blood clot is not treated, it can cause more serious, long-term effects, and occasionally lead to death.

The main questions the study aims to answer are:

  1. How safe is our new blood clot testing method?
  2. How efficient is our new blood clot testing method?

The study will be run in the emergency department and urgent care centre in Kingston, Ontario. Patients who are tested for a DVT in the leg can be included in the study. Researchers follow the patient through chart review to make sure the new system is safe and efficient.

03

Conditions studied

  • Deep Vein Thrombosis (DVT)

Keywords

  • deep vein thrombosis
  • venous thromboembolism
  • emergency medical services
  • diagnosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study participants will be enrolled after a visit to the Kingston Health Sciences emergency department and urgent care centre in Kingston, Ontario.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • emergency physician decides to test for DVT of the lower limb.

Exclusion criteria

Exclusion Criteria:

  • \<18 years of age;
  • tested for DVT without using the ToDay algorithm at the index visit;
  • D-dimer level is known before ToDay item assessment;
  • a new indication for anticoagulation at the emergency department assessment (other than DVT) in a patient not previously prescribed an anticoagulant;
  • a history of prior lower limb DVT, where there is no access to baseline ultrasound imaging;
  • suspected of having a pulmonary embolism;
  • has previously participated in this study;
  • has previously opted out of all research at hospital site;
  • left the emergency department or urgent care centre against medical advice;
  • D-dimer was ordered prior to initial physician assessment;
  • imaging for DVT or pulmonary embolism within the previous 30 days;
  • transferred from another hospital organization.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
458 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. False negative rate of the new DVT testing

    This is the proportion of patients who have DVT excluded by the new ToDay protocol and who were subsequently diagnosed with either a lower limb DVT or pulmonary embolism.

    Time frame: This will be measured at 30-days after the patient's index emergency department visit.

Secondary outcomes

  1. Efficiency of the new DVT testing

    This is the proportion of all study patients who do not require ultrasound imaging at index visit.

    Time frame: At the index emergency department visit.

07

Study locations

1 site
  • Kingston Health Sciences Centre
    Kingston, Ontario K7L2V7, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Dec 2024, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2023
First posted
Jan 8, 2024
StartActual
Jan 1, 2024
Primary completionActual
Dec 1, 2024
CompletionActual
Jan 1, 2025
Last update
May 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06195787
Lead sponsor
Dr. Kerstin de Wit
Collaborators
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
Responsible party
Dr. Kerstin de Wit (Associate Professor Department of Emergency Medicine, Queen's University) — Sponsor-investigator
First posted
Jan 8, 2024
Start date
Jan 1, 2024
Primary completion
Dec 1, 2024
Completion
Jan 1, 2025
Last update
May 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion